HOME >> BIOLOGY >> NEWS
AVAX Technologies' M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma

AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 91st Annual Meeting of the American Association for Cancer Research (AACR), which indicate that M-Vax™, a cancer vaccine made from the patient's own tumor cells, induces T cell infiltration of metastatic sites. T cells are the class of white blood cells believed to be instrumental in fighting cancer cells. The presentation, entitled "T cell receptor structure of lymphocytes infiltrating melanoma metastases after administration of autologous, dinitrophenyl-modified vaccine," showed data that continue to validate earlier results demonstrating that M-Vax elicits an immune response in patients with advanced disease. Most importantly, the data suggest that the vaccine induces the expansion of novel T cell clones, targeted against the tumor. These T cells are involved in controlling immune reactions and may also be the principal agents of anti-tumor effects. The studies were conducted by David Berd, M.D., inventor of the AC Vaccine™ technology and Professor of Medicine, Thomas Jefferson University.

The data reported represent a follow up of earlier work published in 1997 that demonstrate that certain dominant T cell receptor families were identified in nine out of ten melanoma tumors removed from advanced patients who had an immunologic response to M-Vax. In contrast, examination of control specimens - tumors removed from patients before treatment with M-Vax or T cells extracted from blood showed a random pattern of T cells, which would be expected in the absence of an anti-cancer immune response. These findings suggest that treatment with M-Vax results in the expansion of certain groups of T cells that were not present before treatment, and that these T cells specifically target the tumor.

"In previous studies we found that M-Vax caused the development of inflammation in the tumors," Dr. Berd explained. Dr. Berd said that the tumors bec
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext 34
AVAX Technologies, Inc.
3-Apr-2000


Page: 1 2

Related biology news :

1. Palatin Technologies PT-141 increases sexual behavior in female animals
2. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
3. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
4. AVAX Technologies AC Vaccine™ improves relapse-free survival
5. Leader in cancer treatment and prevention research honored
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Chemical derived from vitamin-E shows early promise as cancer drug
8. New molecular link key to cellular proteins involved in cancer progression, other diseases
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Trial shows which brain cancer patients benefit from temozolomide
11. Genetic differences might help distinguish thyroid cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2020)... (PRWEB) , ... May 26, ... ... of enterprise software solutions for biopharmaceutical R&D, today announced that Gritstone Oncology, ... T-cell receptor (TCR)-mimetic bispecific T cell engagers and TCR-based therapeutics, has implemented ...
(Date:5/21/2020)... N.C. (PRWEB) , ... May ... ... , the leading software-as-a-service (SaaS) provider of operations management solutions, today introduced ... BioMed module provides a cloud-based platform for connecting the people and systems ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... ... care across the North Shore and Greater Boston area, is pleased to announce ... As one of the busiest group practices in the area, Agility Orthopedics is ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... In ... commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to ... by Dr MA has been using the zebrafish model to investigate the causes ...
(Date:7/7/2020)... ... ... R3 International is now offering stem cell therapy for Alzheimers dementia in Mexico ... patient's condition, treatment may be offered IV, intrathecal or with a combination. , A ... and the incidence continues to increase as individuals live longer. There is no cure, ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , ... in 2020, despite many obstacles created as a result of COVID-19. As a ... its partnered medical practices and medical manufacturers by expanding access to device offerings, ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight ... microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, ...
Breaking Biology Technology:
Cached News: